- Conditions: Multiple Conditions; Coronary Heart Disease; Diabetes; Hypertension; Chronic Obstructive Pulmonary Disease
Intervention:
Sponsors: University of Southampton; University of Southampton
Not yet recruiting - verified May 2012 - Condition: Carpal Tunnel Syndrome
Intervention: Device: EMS Therasonic 460 Primo Ultrasound therapy
Sponsors: East Kent Hospitals University NHS Foundation Trust; East Kent Hospitals University NHS Foundation Trust
Not yet recruiting - verified May 2012 - Condition: Diabetes
Intervention: Drug: Exenatide, Liraglutide
Sponsors: University of Dundee; Evan Pearson; Newcastle Hospitals NHS trust; Oxford Hospitals NHS trust; Royal Devon & Exeter NHS foundation trust
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Intervention: Procedure: Overnight closed-loop insulin delivery
Sponsors: University of Cambridge; Daniela Elleri; Cambridge University Hospitals NHS Foundation Trust
Not yet recruiting - verified March 2012 - Condition: Painful Diabetic Neuropathy
Interventions: Drug: GRC 17536; Drug: GRC 17536; Drug: Placebo
Sponsors: Glenmark Pharmaceuticals Ltd. India; Glenmark Pharmaceuticals Ltd. India; Glenmark Pharmaceuticals SA
Not yet recruiting - verified March 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Intervention: Drug: Bardoxolone Methyl
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Condition: Prediabetic State
Intervention: Behavioral: Lifestyle Modification
Sponsors: India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals; India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals; Indian Council of Medical Research; Medical Research Council; Imperial College London
Not yet recruiting - verified April 2012 - Conditions: Diabetes; Stroke; Obesity
Intervention:
Sponsors: Children's & Women's Health Centre of British Columbia; Children's & Women's Health Centre of British Columbia
Recruiting - verified March 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Pro insulin peptide; Drug: Pro insulin peptide; Drug: Saline
Sponsors: Cardiff University; Cardiff University; Diabetes Vaccine Development Centre; Juvenile Diabetes Research Foundation
Recruiting - verified April 2012 - Condition: Type 1 Diabetes
Intervention: Other: Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose
Sponsors: Northumbria University; Northumbria University; Diabetes UK
Recruiting - verified February 2012 - Condition: Type 1 Diabetes Mellitus
Intervention: Device: The Imperial College Closed-Loop Insulin Delivery System
Sponsors: Imperial College London; Imperial College London
Recruiting - verified February 2012 - Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: Drug: insulin degludec; Drug: insulin detemir; Drug: insulin aspart
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified May 2012 - Condition: Obesity
Intervention: Device: FreeStyle Navigator
Sponsors: University of Leicester; University of Leicester; University Hospitals, Leicester; Royal College of Surgeons
Not yet recruiting - verified January 2012 - Condition: Type 2 Diabetes,
Intervention: Other: No intervention, observational study
Sponsors: Royal Devon and Exeter NHS Foundation Trust; Royal Devon and Exeter NHS Foundation Trust; National Institute for Health Research, United Kingdom; University of Exeter
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875; Drug: TAK-875; Drug: Glimepiride
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; Juvenile Diabetes Research Foundation; Imperial College London; University of Wisconsin School of Medicine and Public Health; University of Dundee; Merck Serono S.A., Geneva; Itamar-Medical, Israel; University of Western Ontario, Canada; University of Melbourne; Steno Diabetes Center; Maastricht University Medical Center
Recruiting - verified January 2012 - Condition: Painful Diabetic Peripheral Neuropathy (PDPN)
Intervention: Drug: QUTENZA
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012 - Condition: Obesity Hypoventilation Syndrome
Intervention: Behavioral: Rehabilitation
Sponsors: Guy's and St Thomas' NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Type 2 Diabetes; Anxiety; Depression
Intervention: Behavioral: CBT-based Guided Self-Help
Sponsors: University of Edinburgh; University of Edinburgh
Not yet recruiting - verified November 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Comparator: Placebo; Biological: Insulin Glargine; Drug: Metformin
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 1 Diabetes
Interventions: Drug: Diazoxide; Drug: Placebo
Sponsors: University of Dundee; University of Dundee; Juvenile Diabetes Research Foundation
Not yet recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Essential Hypertension
Interventions: Drug: Azilsartan medoxomil; Drug: Azilsartan medoxomil and chlorthalidone; Drug: Azilsartan medoxomil and chlorthalidone
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Centre (Europe) Ltd.
Recruiting - verified January 2012 - Condition: Polycystic Ovary Syndrome
Intervention: Behavioral: Structured Lifestyle Education
Sponsors: University of Leicester; University of Leicester; Society for Endocrinology
Recruiting - verified October 2011 - Conditions: Diabetic Nephropathy; Type 2 Diabetes Mellitus
Interventions: Drug: Placebo; Drug: CCX140-B; Drug: CCX140-B
Sponsors: ChemoCentryx; ChemoCentryx
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Device: ACCU-CHEK AVIVA EXPERT MMOL/L (651); Other: No Intervention
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified August 2011 - Condition: Type 1 Diabetes Mellitus
Interventions: Other: Closed-loop; Other: Conventional insulin pump delivery
Sponsors: University of Cambridge; University of Cambridge; Diabetes UK
Not yet recruiting - verified September 2011 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Insulin glargine; Drug: Insulin detemir
Sponsors: Buckinghamshire Healthcare NHS Trust; Buckinghamshire Healthcare NHS Trust; Novo Nordisk
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Cholestasis of Pregnancy
Intervention:
Sponsors: Imperial College London; Imperial College London
Recruiting - verified December 2011 - Glucose Variability in Type 1 Diabetes and Its Effect on Factors That Influence New Vessel FormationCondition: Type 1 Diabetes
Intervention: Device: Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)
Sponsors: University of Dundee; University of Dundee
Not yet recruiting - verified September 2011 - Conditions: Healthy; Diabetes Mellitus, Type 2
Interventions: Drug: oral NNC 0113-0987; Drug: oral NNC 0113-0987; Drug: I.v. NNC 0113-0987; Drug: oral placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Acromegaly
Intervention: Drug: Active oral octreotide study drug therapy
Sponsors: Chiasma, Inc.; Chiasma, Inc.
Recruiting - verified April 2012 - Condition: Proliferative Diabetic Retinopathy
Intervention: Procedure: Pan retinal Photocoagulation
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Insulin Dependant Diabetes Trust
Not yet recruiting - verified June 2011 - Conditions: Vitamin D Deficiency; Insulin Resistance
Intervention: Drug: Vitamin D3 cholecalciferol
Sponsors: University of Leicester; University of Leicester
Not yet recruiting - verified June 2011 - Condition: Dysglycaemia
Interventions: Procedure: closed-loop insulin delivery; Drug: Usual diabetes treatment regimen
Sponsors: University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Vildagliptin; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention: Biological: Glycaemic optimisation before surgery
Sponsors: Imperial College London; Imperial College London
Recruiting - verified January 2012 - Condition: Diabetic Foot Ulcer
Interventions: Drug: isoniazide; Drug: placebo
Sponsors: Bridge BioResearch Ltd.; Bridge BioResearch Ltd.
Recruiting - verified December 2011 - Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Diabetic Retinopathy; Retinal Neovascularisation
Interventions: Drug: Ranibizumab; Drug: Saline
Sponsors: Moorfields Eye Hospital NHS Foundation Trust; Moorfields Eye Hospital NHS Foundation Trust; Novartis
Recruiting - verified May 2011 - Conditions: Hypertension; Diabetes; Death From Cardiovascular Disease; Myocardial Infarction; Stroke
Intervention:
Sponsors: Imperial College London; Imperial College London; Pfizer
Not yet recruiting - verified December 2011 - Condition: Fatty Liver
Interventions: Drug: Cannabidiol; Drug: Cannabidiol; Drug: Cannabidiol
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.
Recruiting - verified March 2012 - Conditions: Pregnancy Complications; Obesity
Interventions: Drug: Metformin; Drug: Placebo
Sponsors: Epsom and St Helier University Hospitals NHS Trust; Epsom and St Helier University Hospitals NHS Trust; Fetal Medicine Foundation; King's College Hospital NHS Trust
Recruiting - verified January 2012 - Condition: Breast Cancer
Intervention: Drug: Metformin
Sponsors: Oxford University Hospitals NHS Trust; Oxford University Hospitals NHS Trust; Cancer Research UK
Recruiting - verified December 2011 - Condition: Gastroparesis
Interventions: Drug: GSK962040 (5 mg tablet); Drug: GSK962040 (25 mg tablet); Drug: GSK962040 (125 mg tablet); Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012 - Conditions: Diabetic Retinopathy; Macular Oedema
Intervention: Drug: Ranibizumab
Sponsors: Novartis; Novartis
Recruiting - verified April 2012 - Conditions: Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: Bardoxolone Methyl: 20 mg
Sponsors: Reata Pharmaceuticals, Inc.; Reata Pharmaceuticals, Inc.
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes Mellitus; Obesity; Bariatric Surgery
Intervention: Drug: Insulin
Sponsors: Imperial College London; Imperial College London
Recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: glimepride placebo; Drug: linagliptin placebo; Drug: linagliptin; Drug: glimepiride
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes
Intervention: Dietary Supplement: Mirtoselect
Sponsors: University of Aberdeen; University of Aberdeen
Recruiting - verified April 2012 - Condition: Chronic Periodontitis
Intervention:
Sponsors: NHS South Birmingham; NHS South Birmingham; University of Birmingham
Not yet recruiting - verified July 2010 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: liraglutide; Drug: placebo
Sponsors: Novo Nordisk; Novo Nordisk
Recruiting - verified April 2012 - Condition: Diabetic Nephropathies
Interventions: Drug: PF-00489791; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Dapagliflozin; Drug: Placebo matching Dapagliflozin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified November 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Pioglitazone 15 mg; Drug: Pioglitazone 45 mg; Drug: Pioglitazone 30 mg; Drug: BI 1356 / Pioglitazone 15 mg FDC; Drug: BI 1356; Drug: BI 1356 / Pioglitazone 30 mg FDC; Drug: BI 1356 / Pioglitazone 45 mg FDC
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Intervention: Dietary Supplement: Mirtoselect
Sponsors: University of Aberdeen; University of Aberdeen
Recruiting - verified April 2012 - Conditions: Anti- VGF Inhibitor; Diabetic Macular Edema; Diabetic Retinopathy
Intervention: Drug: pega
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: lixisenatide (AVE0010); Drug: placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Diabetes
Interventions: Drug: Isoglycemic Clamp; Drug: Comparator: insulin glargine
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Exenatide Once Weekly; Drug: Placebo
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 low dose; Drug: Placebo BI 10773 high dose; Drug: Placebo BI 10773 high dose; Drug: BI 10773 low dose; Drug: BI 10773 high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Liver Transplant Recipient
Interventions: Drug: Tacrolimus; Drug: Tacrolimus + everolimus; Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Aleglitazar; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified March 2012 - Condition: Diabetes Complications
Interventions: Drug: Ranibizumab; Drug: 0.9% Sodium Chloride
Sponsors: King's College Hospital NHS Trust; King's College Hospital NHS Trust; Novartis
Recruiting - verified February 2011 - Conditions: Diabetes Mellitus, Type 2; Atherosclerosis; Prediabetic State
Interventions: Drug: ACZ885 (Canakinumab); Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Type 2 Diabetes; Obesity
Intervention: Behavioral: 8-month group lifestyle programme
Sponsors: The Royal Bournemouth Hospital; The Royal Bournemouth Hospital
Recruiting - verified August 2011 - Condition: Giant Cell Arteritis
Interventions: Procedure: Ultrasound of temporal and axillary arteries; Procedure: Temporal artery biopsy
Sponsors: University of Oxford; University of Oxford; University of Sheffield; Southend University Hospital; Nuffield Orthopaedic Centre NHS Trust; John Radcliffe Hospital; The Leeds Teaching Hospitals NHS Trust; University of Bristol; London School of Hygiene and Tropical Medicine; Medical Center for Rheumatology Berlin-Buch
Recruiting - verified January 2012 - Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsors: Takeda Global Research & Development Center, Inc.; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide; Drug: insulin lispro
Sponsors: Amylin Pharmaceuticals, Inc.; Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: Diabetic Neuropathy
Intervention:
Sponsors: Tameside Hospital NHS Foundation Trust; Tameside Hospital NHS Foundation Trust
Recruiting - verified May 2009 - Condition: Adipose Tissue
Intervention: Other: GIP (glucose dependent insulinotropic peptide) infusion
Sponsors: Aintree University Hospitals NHS Foundation Trust; Aintree University Hospitals NHS Foundation Trust
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin phosphate; Drug: Placebo
Sponsors: Merck; Merck; Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Recruiting - verified May 2012 - Conditions: Type 1 Diabetes; Type 2 Diabetes
Intervention: Biological: Autologous CD34+ stem cells
Sponsors: Imperial College London; Imperial College London
Recruiting - verified July 2011 - Condition: Diabetes Mellitus, Type 1
Intervention: Drug: Oral Insulin
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); National Center for Research Resources (NCRR); American Diabetes Association; Juvenile Diabetes Research Foundation
Recruiting - verified February 2012 - Conditions: Renal Insufficiency; Diabetes Mellitus
Interventions: Drug: Iodixanol 320 mg I/mL (Visipaque™); Drug: iopamidol 300 mg I/mL (IsoVue)
Sponsors: GE Healthcare; GE Healthcare; ABX-CRO; EMSI; Covance; Quintiles Laboratories; Averion-Hesperion
Recruiting - verified July 2011 - Condition: Diabetes Mellitus, Type 1
Intervention:
Sponsors: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Center for Research Resources (NCRR); Juvenile Diabetes Research Foundation; American Diabetes Association
Recruiting - verified March 2012 - Conditions: Stroke; Myocardial Infarction; Diabetes
Interventions: Drug: pioglitazone; Drug: placebo
Sponsors: Yale University; Yale University; National Institute of Neurological Disorders and Stroke (NINDS); Takeda Pharmaceuticals North America, Inc.
Recruiting - verified August 2011
 |
Join Clinical Trials for Diabetes in United Kingdom |
